Table 2 Available-case analysis of cure and egg reduction rates of 20, 40 and 60 mg/kg praziquantel versus placebo against urogenital schistosomiasis in PSAC and SAC based on the urine filtration method

Infected children before treatment (N)

40

35

41

41

37

45

41

43

Actual dose administered (range; mg/kg)

–

13.6–25

34.6–62.5^a

50–70

–

16.7–23.7

36.4–75^b

56.3–65.6

Cured children after treatment N (%)

19 (47.5)

30 (85.7)

32 (78.0)

28 (68.3)

4 (10.8)

25 (55.6)

28 (68.3)

26 (60.5)

95% CI

32.5–63.9

69.7–95.2

62.4–89.4

51.9–81.9

3.0–25.4

40.0–70.4

51.9–81.9

44.4–75.0

 Male

6 (31.6)

14 (46.7)

19 (59.4)

10 (35.7)

1 (25.0)

9 (36.0)

13 (46.4)

9 (34.6)

 95% CI

12.5–56.6

28.3–65.7

40.6–76.3

18.6–55.9

0.6–80.6

18.0–57.5

27.5–66.1

17.2–55.7

 Female

13 (68.4)

16 (53.3)

13 (40.6)

18 (64.3)

3 (75.0)

16 (64.0)

15 (53.6)

17 (65.4)

 95% CI

43.4–87.4

34.3–71.7

23.7–59.4

44.1–81.4

19.4–99.4

42.5–82.0

33.9–72.5

44.3–82.8

Cured children with light infection

19/40 (47.5)

29/33 (87.9)

28/35 (80.0)

27/37 (73.0)

4/26 (15.4)

24/34 (70.6)

26/33 (78.8)

23/32 (71.9)

Cured children with heavy infections (%)

0/6 (0)

1/2 (50.0)

4/6 (66.7)

1/4 (25.0)

0/11 (0.0)

1/11 (9.1)

2/8 (25.0)

3/11 (27.3)

 Before treatment

7.8

7.5

8.4

8.3

31.5

21.6

16.6

17.2

 After treatment

2.4

0.1

0.2

0.3

13.1

0.5

0.2

0.4

 Egg reduction rate

68.9

98.3

97.6

96.5

58.5

97.6

98.6

97.6

 (95% CI)

46.6–83.6

95.4–99.8

94.9–99.2

93.1–98.7

38.7–71.4

96.4–98.6

97.7–99.3

95.3–98.9

 Before treatment

22.7

14.3

21.7

16.9

94.4

89.5

31.0

34.4

 After treatment

11.5

0.3

0.4

0.9

49.0

1.2

0.4

1.0

 Egg reduction rate

49.5

97.8

98.2

94.5

46.9

98.7

98.8

97.0

 (95% CI)

0.2–77.3

93.6–99.9

96.1–99.5

85.7–99.1

36.4–77.6

96.7–99.3

97.7–99.5

92.9–99.2